Biomoda files additional patent protection for lung cancer detection technology

Biomoda, Inc. has confirmed that it is continuing to expand its patent portfolio with a unique patent pending for the use of its patented porphyrin molecule to detect different cell variations of lung cancer.

"It is important that the Company protect all the various uses of this molecule, setting up a barrier to entry for competition," said John Cousins, President of Biomoda. "We are protecting the value of our core patents with patents that detail improvements and new uses of our strong, innovative technology. This prevents those on the periphery from attempting to target our patents with a so-called 'picket fence' of minor patents that could weaken our powerful market position."

"This additional patent, filed in Washington D.C., just days ago, and only two weeks after the Company's most recent patent filing, underscores the critical importance of protecting valuable proprietary technology. This new patent details a number of ways that a mixture of porphyrin molecules will bind in special ways with the different types of lung cancer," Mr. Cousins said.

"The lighting characteristics of cancer cells, which glow red under fluorescent light after binding with the Biomoda molecules and can be viewed under a microscope, will vary depending on the cell type of the cancer and the patent explains these characteristics," added Dr. Herbert Whitaker, Biomoda's Director of Research.

The Mayo Clinic (Rochester, Minnesota) and Biomoda are jointly conducting a broad validation study of Biomoda's patented technology, a non-invasive cytology based lung cancer diagnostic assay.